| Japanese |
|---|
| Title | 新しい肝機能イメージング剤99mTc-GSAの第1相臨床試験 |
|---|
| Subtitle | 原著 |
|---|
| Authors | 鳥塚莞爾*, 池窪勝治**, 河相吉***, 菅豊***, 田中敬正***, 日野恵**, 伊藤秀臣**, 山本和高****, 米倉義晴**** |
|---|
| Authors(kana) | |
|---|
| Organization | *福井医科大学, **神戸市立中央市民病院核医学科, ***関西医科大学放射線科, ****京都大学医学部核医学科 |
|---|
| Journal | 核医学 |
|---|
| Volume | 28 |
|---|
| Number | 11 |
|---|
| Page | 1321-1331 |
|---|
| Year/Month | 1991/11 |
|---|
| Article | 原著 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 「要旨」肝臓に特異的に存在するアシアロ糖蛋白受容体をターゲットとした新しい肝機能イメージング用放射性医薬品99mTc-GSAの第1相臨床試験を実施した. 健常成人男子7例を対象とした. 投与放射能量は185MBq(5mCi), 投与リガンド量は1〜10mgとした. 99mTc-GSAに起因すると考えられる自・他覚症状の変化および臨床検査値の異常は認められず, 抗GSA抗体の産生も認められなかった. 全例において明瞭な肝シンチグラムが得られた. 99mTc-GSAの体内動態の検討は5例について行った. 99mTc-GSAは静注後急速に肝臓に摂取され, その後胆道系へ緩徐に排泄され, 一部は尿路系へ排泄された. 投与後早期の血中消失および肝集積は投与リガンド量が増加するほど遅延し, 受容体を介した臓器集積に特徴的な用量依存性が認められた. これらの結果から, 99mTc-GSAによる肝臓の受容体量に基づいた肝機能評価の可能性が示唆された. |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | Technetium-99m-DTPA-galactosyl human serum albumin (99mTc-GSA), Neoglyco-protein, Asialoglycoprotein receptor imaging, Bio-distribution, Safety evaluation. |
|---|
| English |
|---|
| Title | Phase I Clinical Study on 99mTc-GSA, a New Agent for Functional Imaging of the Liver |
|---|
| Subtitle | |
|---|
| Authors | Kanji TORIZUKA*, San Kil Ha-KAWA**, Katsuji IKEKUBO***, Yutaka SUGA**, Yoshimasa TANAKA**, Megumu HINO***, Hidetomi ITO***, Kazutaka YAMAMOTO****, Yoshiharu YONEKURA**** |
|---|
| Authors(kana) | |
|---|
| Organization | *Fukui Medical School, **Department of Radiology, Kansai Medical University, ***Department of Nuclear Medicine, Kobe City General Hospital, ****Department of Nuclear Medicine, Kyoto University Faculty of Medicine |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 28 |
|---|
| Number | 11 |
|---|
| Page | 1321-1331 |
|---|
| Year/Month | 1991/11 |
|---|
| Article | Original article |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | [Summary]Technetium-99m-DTPA-galactosyl human serum albumin (99mTc-GSA) is a new radiopharmaceutical which binds to the asialoglycoprotein receptors located specifically on the hepatocytes. Phase I study of 99mTc-GSA was performed on seven normal volunteers, who were intravenously injected with 185 MBq (5 mCi) and 1-10 mg of 99mTc-GSA. None of adverse reactions, abnormal findings of laboratory test and anti-99mTc-GSA antibody production was recognized. The livers were clearly visualized in all subjects. In the pharmacokinetic analyses on five subjects, 99mTc-GSA was rapidly taken up by the livers immediately after the injection and was slowly excreted through the biliary tracts and the urinary tracts. Dose-dependency which is a specific feature for the receptor-mediated agents was observed; the blood clearances of 99mTc-GSA were prolonged in pro-portion to the injected ligand doses. These results suggest that 99mTc-GSA may be a potential agent for evaluating hepatic functions based on the hepatic receptor quantities. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | Technetium-99m-DTPA-galactosyl human serum albumin (99mTc-GSA), Neoglyco-protein, Asialoglycoprotein receptor imaging, Bio-distribution, Safety evaluation. |
|---|